Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo Capsule

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,692 result(s) found for: Placebo Capsule. Displaying page 46 of 135.
    «« First « Previous 42  43  44  45  46  47  48  49  50  Next» Last»»
    EudraCT Number: 2019-004021-25 Sponsor Protocol Number: IM026-024 Start Date*: 2021-10-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus.
    Medical condition: Active Systemic Lupus Erythematosus.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004457-88 Sponsor Protocol Number: SPD489-346 Start Date*: 2014-03-05
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eati...
    Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003634-15 Sponsor Protocol Number: CQAB149B2211 Start Date*: 2006-09-13
    Sponsor Name:NovartisPharma Services AG
    Full Title: An exploratory, double-blind comparison of inspiratory capacity (IC) and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open-label b.i.d. administration o...
    Medical condition: Mild to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019028-30 Sponsor Protocol Number: CFTY720D2320 Start Date*: 2010-07-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 3-month blinded, randomized, multicenter, placebocontrolled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus t...
    Medical condition: Relapsing forms of multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048393 Multiple sclerosis relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) FR (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002894-24 Sponsor Protocol Number: C4671006 Start Date*: 2021-08-23
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF-07321332/RITONAVIR IN PREVENTING SYMPTOMATI...
    Medical condition: SARS-CoV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-004653-69 Sponsor Protocol Number: BHV4157-303 Start Date*: 2021-09-27
    Sponsor Name:Biohaven Pharmaceuticals, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10002860 Anxiety disorder NEC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005521-73 Sponsor Protocol Number: GLPG0974-CL-201 Start Date*: 2013-03-20
    Sponsor Name:Galapagos NV
    Full Title: Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GLPG0974 in sub...
    Medical condition: Mild to moderate Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) LV (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2012-003309-91 Sponsor Protocol Number: SPD489-343 Start Date*: 2013-03-20
    Sponsor Name:Shire Development, LLC
    Full Title: The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Ag...
    Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001766-40 Sponsor Protocol Number: DRI5165 Start Date*: 2004-12-20
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: Placebo controlled double blind dose ranging study of the efficacy and safety of SSR149744C 50, 100, 200, or 300 mg OD, with amiodarone as calibrator for the maintenance of sinus rhythm in patients...
    Medical condition: Atrial fibrillation/flutter
    Disease: Version SOC Term Classification Code Term Level
    7.0 10003658 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) DK (Completed) IT (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004243-92 Sponsor Protocol Number: JZP110-405 Start Date*: 2021-06-18
    Sponsor Name:Jazz Pharmaceuticals, Inc.
    Full Title: Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter S...
    Medical condition: Impaired cognitive function in patients with excessive daytime sleepiness associated with obstructive sleep apnea
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-006451-39 Sponsor Protocol Number: A0221046 Start Date*: 2008-02-20
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) LT (Completed) ES (Completed) HU (Completed) GR (Completed) EE (Completed) LV (Completed) SK (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-001448-21 Sponsor Protocol Number: MS200527-0086 Start Date*: 2017-02-16
    Sponsor Name:Merck KGaA
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Effic...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) CZ (Completed) PL (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002455-42 Sponsor Protocol Number: WO41554 Start Date*: 2020-08-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN ...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Completed) HU (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004310-19 Sponsor Protocol Number: W00090GE303/EORTC-2139-MG Start Date*: 2022-02-15
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group
    Medical condition: Resected BRAF V600E/K stage IIB/C melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NO (Completed) AT (Completed) NL (Completed) PL (Completed) GR (Completed) CZ (Completed) HU (Completed) ES (Ongoing) PT (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006022-25 Sponsor Protocol Number: WA28119 Start Date*: 2013-05-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS
    Medical condition: Giant cell arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) AT (Completed) DE (Completed) DK (Completed) GB (Completed) PT (Completed) NL (Completed) ES (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-005029-19 Sponsor Protocol Number: CV010031 Start Date*: 2020-06-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarc...
    Medical condition: Ischemic Stroke or Transient Ischemic Attack (TIA)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Ongoing) SE (Completed) HU (Completed) NO (Completed) FI (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DK (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001502-18 Sponsor Protocol Number: I3YMCJPBM Start Date*: 2014-11-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women ...
    Medical condition: Hormone Receptor Positive, HER2 negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in This Disease Setting
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) ES (Ongoing) IT (Completed) SK (Completed) BE (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004040-70 Sponsor Protocol Number: BUC-56/PBC Start Date*: 2008-05-15
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsu...
    Medical condition: PBC patients with an incomplete response to UDCA treatment defined by the failure to achieve s-AP levels < 1.5x upper limit of normal after at least 6 months of treatment with UDCA and with inflamm...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) AT (Completed) NL (Completed) FI (Completed) ES (Completed) HU (Completed) GB (Completed) LT (Completed) DK (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-008748-26 Sponsor Protocol Number: CQAB149B2312 Start Date*: 2009-05-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio fase IIIb, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 2 periodos cruzados, para evaluar el efecto de indacaterol (150 µg o.d.), en pacientes con enfermedad pulmona...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004195-30 Sponsor Protocol Number: ABX464-004 Start Date*: 2016-05-24
    Sponsor Name:Abivax
    Full Title: A multi-center, randomized, double-blind, placebo-controlled Phase IIa trial to compare the safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with ...
    Medical condition: Human Immunodeficiency Virus (HIV)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10020443 Human immunodeficiency virus syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 42  43  44  45  46  47  48  49  50  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:24:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA